



# Creating Lasting Value

Investor Presentation – August 2020



NSE:SUNPHARMA | BSE:524715 |  
Bloomberg:SUNP IN | Reuters:SUN.BO

[WWW.SUNPHARMA.COM](http://WWW.SUNPHARMA.COM)

# Disclaimer

Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", "seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue" and similar expressions or variations of such expressions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. Sun Pharmaceutical Industries Limited does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

# Contents



**1**

**Sun Pharma at a glance**

**2**

**Long-term Strategy**

**3**

**Global Specialty Initiatives**

**4**

**Revenue Composition, History & Acquisition Track Record**

**5**

**Business Operations, R&D, Manufacturing**

**6**

**Corporate Governance**

**7**

**Financials – P&L, Balance Sheet, Cash Flows & Ratios**

**8**

**Key Milestones Targeted**

# Sun Pharma at a glance



4<sup>th</sup> Largest Global Specialty Generic Company\*

US

- Ranked 9<sup>th</sup> in US Generics Market<sup>##</sup>

India

- No. 1 Pharma Company in India

Emerging Markets

- Amongst the largest Indian Pharma Company in Emerging Markets

Rest of World

- Expanding presence in Rest of World

Manufacturing Footprint

- 43 manufacturing sites across the world

Market Presence

- Presence in more than 100 countries across branded and generic markets

Employees

- 36,000+ global employee base

Quality Compliance

- Multiple manufacturing facilities approved by various regulatory authorities across the world including USFDA

R&D and Manufacturing

- Capabilities across dosage forms like injectables, sprays, ointments, creams, liquids, tablets and capsules

Addressable Segments

- Specialty products, branded generics, complex generics, pure generics & APIs


\*Source: Evaluate Pharma Estimates for 12 months ended Dec 2019

## Source: IQVIA data for 12 months ended April 2020

# World's 4th Largest Specialty Generic Pharma Co



2019 Worldwide Generic Sales (US\$ in billions)



Source: Evaluate Pharma Estimates for 12 months ended Dec 2019

# Sun Pharma today



## US Formulations

- 9<sup>th</sup> largest generics company in US\* with a strong pipeline (95 ANDAs & 6 NDAs awaiting approval)
- Presence in generics, Specialty branded segments with more than 546 approved products
- FY20 sales: US\$ 1,487 mn <sup>(2)</sup>

## India Branded Generics

- No.1 ranked with 11 classes of doctor categories
- Leading position in high growth chronic therapies
- Specializes in technically complex products
- FY20 sales: US\$ 1,369 mn <sup>(2)</sup>



## Emerging Markets

- Presence in about 80 countries across Africa, Americas, Asia and Eastern & Central Europe
- Key focus markets – Romania, Russia, South Africa, Brazil & Mexico and complementary & affiliated markets
- FY20 sales: US\$ 776 mn <sup>(2)</sup>

## Western Europe, Canada, Japan ANZ & others

- Presence across majority of markets in Western Europe, Canada, Japan and A&NZ
- Product portfolio includes differentiated offerings for hospitals, injectables and generics for retail market
- FY20 sales: US\$ 638 mn <sup>(2)</sup>

Note:

(1) As of Sept, 17, 2020 using spot exchange rate of INR /USD = 73.74

(2) Using average exchange rate for FY20 of INR /USD = 70.91

# Includes Western Europe, Canada, Australia & New Zealand, Japan and other markets.


All sales numbers in US\$ for 12 months ended March 31, 2020.

\* Source: IQVIA data for 12 months ended April 2020

# Driving Long Term Growth

- Enhance share of specialty business globally
- Achieve differentiation by focusing on technically complex products
- Focus on key markets – achieve critical mass
- Speed to market
- Ensure sustained compliance with global regulatory standards

- Optimize operational costs
- Vertically integrated operations



- Increasing contribution of specialty and complex products
- Future investments directed towards differentiated products

- Use acquisitions to bridge critical capability gaps
- Focus on access to products, technology, market presence
- Ensure acquisitions yield high return on Investment
- Focus on payback timelines

# Our Specialty Portfolio



## Ilumya/ Ilumetri

- Indication - For plaque psoriasis
- Launched in US in October 2018
- Phased launch in Europe by Almirall starting December 2018 onwards
- Launched in Australia in December 2018
- Long term clinical data shows that the significant response rate seen in 52 & 64 weeks were maintained over four years
- Evaluating new indications for Ilumya - Late-breaking phase 2 data shows potential to improve joint & skin symptoms of Psoriatic Arthritis
- Out licensed to CMS for Greater China market in June 2019
- Launched in Japan in September 2020

## Cequa

- Indication - For dry eye disease
- Launched in US in October 2019
- Out-licensed to CMS for Greater China market in June 2019

## Absorica

- Indication - For the treatment of severe recalcitrant nodular acne
- Currently marketed in US
- Launched Absorica LD Capsules in the U.S. in Feb-2020

## Levulan Kerastick

- Indication – In combination with BLU-U (Blue Light Photodynamic Therapy Illuminator) for treatment of minimally to moderately thick actinic keratoses of the face, scalp, or upper extremities.
- Currently marketed in US for actinic keratosis



# Our Specialty Portfolio



## Odomzo

- Indication - For LABCC (locally advanced basal cell carcinoma)
- Currently marketed in US, Germany, France, Denmark, Switzerland, Australia and Israel

## Yonsa

- Indication - For metastatic castration resistant prostate cancer in combination with methylprednisolone
- Launched in US in May 2018

## Bromsite

- Indication - For prevention of ocular pain & treatment of inflammation following cataract surgery
- Launched in US in November 2016


## Xelpros

- Indication - For reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension
- BAK (Benzalkonium chloride) free form of latanoprost
- Launched In US in January 2019

## Infugem/ InfuSMART

- Gemcitabine (chemotherapy product) in pre-mixed ready to use bags
- Launched in Europe in July 2016
- Launched in US in April 2019

# Highly Diversified Revenue Base









# Includes Western Europe, Canada, Japan , Australia, New Zealand and other markets.

# Impressive Track Record of Growth




(All Figures in USD Million)




# Consistent profitability and returns




## Gross Margin #




## EBITDA Margin




## Net Margin (adjusted)




## ROCE



## ROE



## Market Cap (USD Bn)




# Gross margin= (Net Sales- Material Cost)/ Net Sales \* 100  
ROCE & ROE exclude one-time exceptional charges

(Market Cap as on 31st March )


# Profitability




## Gross Margin



## EBITDA Margin



## Net Margin




Gross margin= (Net Sales – Material Cost) / Net Sales \* 100

—●— Sun Pharma    ■ Range of Top 9 Indian Pharma Cos.    —●— Average

#Top 9 Indian Pharma company include Aurobindo, Cadila Healthcare, Cipla, DRL, Glenmark, Ipca, Lupin, Torrent and Wockhardt.

# Creating a Global Company



## Sun Pharma Today



36,000+ Global Employee Base



Invested over USD 2.9 Bn in R&D till date



Part of NSE Nifty & BSE Sensex in India



43 Manufacturing facilities in 6 Continents



69% of sales from international markets

# Key Deals & Rationale



Year	Deals	Country	Rationale
2020	Exclusive licensing agreement with Himka for Ilumya	Middle East & North Africa	Registration and commercialization of the product in all Middle East & North Africa (MENA) markets.
2020	Licensing agreement with SPARC for SCD-044	Global	Potential treatment for atopic dermatitis, psoriasis and other auto-immune disorders
2020	In-licensed Triferic brand from Rockwell Medical Inc. (USA)	India	Expands nephrology portfolio in India - for treating anaemia in hemodialysis patients.
2019	Licensing agreement with Astrazeneca UK for ready-to-use infusion oncology products	Mainland China	Access to oncology market in Mainland China
2019	Licensing agreement with CMS for Tildrakizumab, Cequa & 8 generic products	Greater China	Access to Greater China market
2018	Acquired Pola Pharma in Japan	Japan	Access to Japanese dermatology market.
2016	Acquired global rights for Cequa & Odomzo	Global	Enhances specialty pipeline.
2016	Acquired Biosintez	Russia	Local manufacturing capability to enhance presence in Russian market
2016	Licensing agreement with Almirall for Tildrakizumab for Psoriasis	Europe	Access to European market for Tidrakizumab


# Key Deals & Rationale




Year	Deals	Country	Rationale
2016	Acquired 14 brands from Novartis	Japan	Entry into Japan
2016	Distribution agreement with AstraZeneca	India	Distribution services agreement in India for brand "Oxra" & "Oxramet"® (brands of dapagliflozin, used for diabetes treatment)
2016	Distribution agreement with AstraZeneca	India	Distribution services agreement in India for brand "Oxra" & "Oxramet"® (brands of dapagliflozin, used for diabetes treatment)
2015	Acquired InSite Vision Inc.	US	Strengthens branded ophthalmic portfolio in U.S.
2015	Distribution agreement with AstraZeneca	India	Distribution services agreement in India for brand "Axcer"® (brand of ticagrelor, used for the treatment of acute coronary syndrome)
2015	Sun Pharma – Ranbaxy Merger	Global Markets	Strengthen position in the Global Generic Pharma Industry, No.1 Pharma Company in India & Strong positioning in Emerging Markets
2014	In-licensing agreement with Merck for Tildrakizumab a biologic for psoriasis	Global Markets	Strengthening the specialty product pipeline
2014	Acquired Pharmedica	US	Access to sterile injectable capacity in the US
2012	Acquired DUSA Pharma, Inc.	US	Access to specialty drug-device combination in dermatology segment
2010	Acquired Taro Pharmaceutical Industries Ltd.	Israel	Access to dermatology generic portfolio Manufacturing facilities at Israel & Canada
1997	Acquired Caraco	Detroit, US	Entry into US Market




# Successful track record of turning around acquisitions



# US Business



**33% of Revenues**



# US Business at a glance



9<sup>th</sup> Largest Pharma Company in the US Generics Market \*

## Dermatology Segment

- Ranked 2<sup>nd</sup> by prescriptions<sup>##</sup> in the US dermatology market

## Comprehensive Portfolio

- Wide basket of 586 ANDAs & 61 NDAs filed and 491 ANDAs & 55 NDAs approved across multiple therapies

## Robust Pipeline

- 95 ANDAs & 6 NDAs pending with FDA

## Market Presence

- Presence in generics, branded & OTC segments

## Flexible Manufacturing

- Integrated manufacturer with flexibility for manufacturing onshore/ offshore


## Dosage Forms

- Liquids, Creams, Ointments, Gels, Sprays, Injectable, Tablets, Capsules, Drug-Device combination

\* Source: IQVIA data for 12 months ended April 2020

## Source: IQVIA data for 12 months ended April 2020

# US Business – Sales buildup & Key milestone




Key Milestones in US	
FY98	•Entry in US through Caraco acquisition
FY10	•Acquired Taro Pharma – Entry into US dermatology market
FY13	•Acquired DUSA - Entry in branded specialty market
FY16	•Acquired InSite Vision – Strengthen ophthalmic portfolio
FY17	•Tildrakizumab filing in US & Europe •Acquired Ocular Technologies giving access to Cequa, a product for dry eyes. •Launched BromSite in US •Acquired Odomzo- branded oncology product from Novartis
FY18	•Launched Odomzo in US •US FDA approval for Ilumya
FY19	•Launched Ilumya & Yonsa in US •Received USFDA approval for Cequa •Launched Xelpros in US •Launched Ready-to-Infuse INFUGEM™
FY20	•Launched Cequa in US • Launched Absorica LD Capsule in US in Jan-2020

# ANDA Pipeline - Significant ramp up




## ANDAs Filed and Approved (Cumulative)




(Cumulative no's for FY16 are lower than FY15 due to Bryan facility divestment. Ranbaxy numbers added wef March'15)

## ANDA Approvals by Therapeutic Area



(As of June'20)

# India Branded Generic Business



# India Business at a glance



## No. 1 in India

### Market Position\*\*

- No. 1 ranked with 8.2% market share

### Prescription Ranking###

- No. 1 ranked by prescriptions with 11 different classes of doctors

### Chronic Segment

- Market leader in the chronic segment

### Acute Segment

- Strong positioning in the acute segment

### Product Offering

- Specializes in technically complex products and offers a complete therapy basket

### Strong Brand Positioning\*\*

- 30 brands in the country's top 300 pharmaceutical brands

### De-risked Growth\*\*

- Top 10 Brands contribute approx. 18% of India revenues
- Growth driven by a basket of brands – low product concentration


### Extensive Sales Force

- 10,900+ strong field force

\*\* - As per AIOCD AWACS data for 12 months ended June'20

### - As per SMSRC data for Feb'20

# Largest Pharma Company in India




Source: AIOCD AWACS MAT June 2020 data converted at average of Rs. 72.49/US\$




# India Business – Sales ramp-up



Leadership in chronic segment; Strong positioning in acute segment  
30 brands in top 300 brands of country



## Therapeutic Revenue Break-up



• As per AIOCD AWACS – June '20

# Leadership in key therapeutic areas\*



Number 1 Ranking with 11 Doctor Categories\*


Specialist	Prescription Ranking				
	Feb '16	Feb '17	Feb '18	Feb '19	Feb '20
Psychiatrists	1	1	1	1	1
Neurologists	1	1	1	1	1
Cardiologists	1	1	1	1	1
Orthopaedic	1	1	1	1	1
Gastroenterologists	1	1	1	1	1
Nephrologists	1	1	1	1	1
Diabetologists	1	1	1	1	1
Dermatologists	1	1	1	1	1
Urologists	1	1	1	1	1
Consulting Physicians	1	1	1	1	1
ENT	2	2	2	2	1
Ophthalmologists	1	2	1	1	2
Chest Physicians	1	2	1	2	2

\*Ranks based on prescription share

Source-Strategic Marketing Solutions and Research Centre (SMSRC) Prescription Data


# Best-in-class field force productivity

## Sales Per Representative (USD '000)




- Well trained and scientifically oriented sales representatives team with strong performance track record
- Field force with highest productivity amongst key players in India
- Currently in the process of expanding the sales force strength to enhance geographical & doctor reach and improve brand focus

# Emerging Markets



**17% of Revenues**



# Emerging Markets Business at a glance



## Largest Indian Company in Emerging Markets

### Global footprint

- Presence in about 80 markets

### Focus Markets

- Romania, Russia, South Africa, Brazil, Mexico and complementary & affiliated markets

### Product Portfolio

- Extensive basket of branded products

### Customer Focus

- Strong relationships with doctors and medical practitioners

### Sales Force

- Approximately 2,300 Sales Representatives


### Opportunity

- To cross-sell products between Sun Pharma and Ranbaxy marketing infrastructure


### Local Manufacturing

- Across 7 countries

# Western Europe, Canada, Japan, ANZ & Other Markets



14% of Revenues



# Western Europe & Other Markets at a glance



## Amongst the leading Indian Companies

### Market Presence

- Across all major markets in Western Europe, Canada, A&NZ, Japan and few other markets

### Product Portfolio

- Expanding basket of products including injectables and hospital products as well as products for retail market

### Focus

- Development and commercialization of complex generics and differentiated products to drive sustainable and profitable growth

### Sales Force

- Distribution led model

### Local Manufacturing

- At Canada, Japan, Australia, Israel and Hungary + Servicing from India facilities

### Japan Presence

- Acquired 14 established prescription brands from Novartis in March'16.
- Acquired Pola Pharma in Japan in Jan'19

# Global Consumer Healthcare Business





# Global Consumer Healthcare Business at a glance



## An Attractive Opportunity

India

- Amongst the top 10 consumer healthcare companies

Global Presence

- Operates in about 20+ countries

Focus Markets

- Romania, Russia, South Africa, Nigeria, Myanmar, Ukraine, Poland, Thailand, Belarus, Kazakhstan, Morocco, UAE & Oman

Strong Brand Equity

- Enjoy strong brand equity in 4 countries


Sales Force

- Promoted through dedicated sales force in each market

Strong Positioning

- Amongst top 10 consumer healthcare companies in India, Romania, Nigeria & Myanmar

# Active Pharmaceutical Ingredients (API) Business



## Backward Integration – Strategic Importance

### Strategic Importance

- Backward integration provides cost competitiveness and supply reliability

### Customers

- Large generic and innovator companies

### Product Portfolio

- Approximately 300 APIs

### Pipeline Development

- Approx. 20 APIs scaled up annually

### Regulatory approvals

- 325 DMF/CEP approvals to date
- 434 DMF/CEP Filings to date

### Manufacturing

- Across 14 facilities

# Research & Development



# Research & Development



Cumulative R&D Spend of USD 2.9 billion to date

## R&D Spend

- R&D spend at 6.1% of Sales for FY20
- Strong cash flows & large scale to support R&D investments

## Capabilities

- Strong research teams in generics, finished dosage development, biological support, chemistry

## Organization

- Approx. 2,500 headcount globally with capabilities across dosage forms like orals, liquids, ointments, gels, sprays, injectable

## IPR Support

- Strong team of intellectual property experts supporting R&D


## Focus

- Developing non infringing formulations and development of specialty/complex products

# R&D Investments




## R&D Investments




■ R&D Investments USD Mn) ■ R&D Investments (% of Sales)

## Filings and Approvals



As of June 30, 2020

# Global Manufacturing Presence



# Global Manufacturing Presence



## World Class Manufacturing Infrastructure

### Extensive Global Footprint

- 43 manufacturing facilities across India, the Americas, Asia, Africa, Australia and Europe

### Integrated Network

- Vertically integrated network across six continents enabling high quality, low cost and a quick market entry across the geographies

### Capabilities

- One of the few companies that has set up completely integrated manufacturing capability for the production of oncology, hormones, peptides, controlled substances and steroidal drugs

### High Quality

- High quality manufacturing facilities. Many of the plants have received approvals from US FDA, UK MHRA and various other regulatory authorities

### Dosage Forms

- Ability to manufacture a variety of dosage forms – Orals, Creams, Ointments, Injectables, Sprays, Liquids



# Finished Dosage Manufacturing

## 29 Finished dosage manufacturing sites

- India : 14, US : 3, Japan : 2
- Canada, Hungary , Israel, Bangladesh, South Africa, Malaysia, Romania, Egypt, Nigeria and Russia : 1 each
- Capacities available for a variety of finished dosages

### Orals

- Tablets / Capsules
- Semisolids
- Liquids
- Suppository

### Injectables / Sterile

- Vials
- Ampoules
- Pre-filled Syringes
- Gels
- Lyophilized Units
- Dry powder
- Eye drops
- MDI
- Aerosols

### Topicals

- Creams
- Ointments

# API Manufacturing

## 14 API manufacturing locations

- India : 9, Australia : 2, Israel : 1, US : 1, Hungary : 1

### Panoli & Ahmednagar (both India)

- International regulatory approvals: USFDA, European
- Stand alone units for peptides, anti-cancer, steroids, sex hormones

**API**  
Key Plants



### Australia, Hungary & Tennessee (US)

- Controlled substances manufacture

# Corporate Governance

Our philosophy on corporate governance envisages working towards high levels of transparency, accountability and consistent value systems across all facets of operations



## Chairman



### **Israel Makov**

Former President & CEO of Teva Pharma. Industries Ltd.

## Independent Director



### **Rekha Sethi**

Director General  
All India Management  
Association (AIMA)

## Independent Director



### **Vivek C. Sehgal**

Chairman, Samvardhana  
Motherson Group &  
Motherson Sumi Systems  
Ltd.

## Independent Director



### **Gautam B. Doshi**

Professional with expertise  
in M&A, Taxation, Accounting  
& Corporate and Commercial  
Laws.

# Financials



# Financials



Market Capitalisation Rs. 1,200 billion / US\$ 17 billion (as of 17<sup>th</sup> Sept 2020)

( All Figures in USD. Mn )

	FY16	YoY	FY17	YoY	FY18	YoY	FY19**	YoY	FY20	YoY
<b>P&amp;L Summary</b>										
Sales	4,262	-4%	4,512	6%	4,044	-10%	4,101	1%	4,559	11%
Gross Profit	3,295	-2%	3,300	0%	2,892	-12%	2,976	3%	3,257	9%
EBITDA	1,155	-9%	1,308	13%	804	-39%	847	5%	913	8%
Net Profit	695	-6%	1,038	49%	325	-69%	381	17%	531	39%
Net Profit (Adjusted)	799 <sup>#</sup>	2%	1,038	30%	512 <sup>#</sup>	-51%	555 <sup>#</sup>	8%	568 <sup>#</sup>	2%
R&D Spend	352	10%	345	-2%	349	1%	284	-19%	278	-2%

<b>BS Summary</b>	Mar'16	YoY	Mar'17	YoY	Mar'18	YoY	Mar'19	YoY	Mar'20	YoY
Shareholders Funds	4,972	11%	5,650	14%	5,901	4%	5,987	1%	6,004	0%
Loan Funds	1,254	4%	1,248	0%	1,502	20%	1,430	-5%	1,005	-30%
Net Fixed Assets	1,871	21%	2,304	23%	2,420	5%	2,500	3%	2,333	-7%
Investments	276	-51%	184	-33%	1,100	499%	1,143	4%	1,345	18%
Cash and Bank Balances	1,987	13%	2,335	17%	1,529	-35%	1,052	-31%	861	-18%
Inventory	968	7%	1,054	9%	1,060	1%	1,140	8%	1,045	-8%
Sundry Debtors	1,022	26%	1,111	9%	1,204	8%	1,284	7%	1,250	-3%
Sundry Creditors	540	4%	678	25%	734	8%	600	-18%	543	-9%

#

FY16- Adjusted for USD 104 Mn of exceptional items related to Ranbaxy integration

FY18- Adjusted for USD 187 Mn provision related to Modafinil settlement & deferred tax adjustment

FY19- Adjusted for USD 174 Mn provision related to Modafinil settlement


FY20- Adjusted for USD 37 Mn provision related to settlement with Govt. Authorities USA and Indirect Tax impact of Sikkim & Samba

\*\* FY19- – Includes a one-time sales reduction of USD 155 Mn related to change in distribution for India business


# Sales Break-up



## In INR Billion



## In USD Million




#Exchange Rate : US\$1 = Rs 64.46 (for FY18)  
 US\$1 = Rs 69.95 (for FY19)  
 US\$1 = Rs 70.91 (for FY20)

# EBITDA Trend





## In USD Billion



# Cash Flow

## Net Cash From Operating Activities (USD Mn)

## Free Cash Flow (USD Mn)





# Financial Ratios



	FY16	FY17	FY18	FY19 **	FY20
<b>Growth (%)</b>					
Sales	(4.4)	5.9	(10.4)	1.4	11.2
Gross Profit	(1.8)	0.2	(12.4)	2.9	9.4
EBITDA	(8.5)	13.2	(38.5)	5.4	7.8
Net Profit	(6.4)	49.5	(68.7)	17.2	39.3
Net Profit (Adjusted)	2.3 #	29.9	(50.7) #	8.3 #	2.4 #
<b>Margins (%)</b>					
Gross Margin	77.3	73.1	71.5	72.6	71.4
EBITDA Margin (%)	27.1	29.0	19.9	20.7	20.0
Net Margin	16.3	23.0	8.0	9.3	11.6
Net Margin (Adjusted)	18.8 #	23.0	12.7 #	13.5 #	12.5 #
<b>Return (%)</b>					
ROCE	14.8	16.1	7.8	8.5	8.3
ROE	17.6	19.8	8.9	9.4	9.1
<b>Others</b>					
Debt / Equity	0.25	0.22	0.25	0.24	0.17
Fully Diluted EPS	0.3	0.4	0.1	0.2	0.2
Fully Diluted EPS (Adjusted)	0.3 #	0.4	0.2 #	0.2 #	0.2 #
<b>R&amp;D Spend % of Net Sales</b>					
Revenue	7.9	7.1	7.9	6.7	5.9
Capital	0.3	0.6	0.7	0.3	0.2

#  
FY16- Adjusted for USD 104 Mn of exceptional items related to Ranbaxy integration  
FY18- Adjusted for USD 187 Mn provision related to Modafinil settlement & deferred tax adjustment  
FY19- Adjusted for USD 174 Mn provision related to Modafinil settlement  
FY20- Adjusted for USD 37 Mn provision (related to Dusa US DoJ settlement of USD 23 Mn and Indirect Tax provision of USD 14 Mn in India)  
\*\* FY19- – Includes a one-time sales reduction of USD 155 Mn related to change in distribution for India business

# Key Financials Q1 FY21



( All Figures in USD Mn )

	Q1 FY21	Q1 FY20	CHANGE	FY20	FY19	CHANGE
Sales	984	1,187	-17.1%	4,559	4,101	11.2%
Gross Profit	725	834	-13.1%	3,257	2,976	9.4%
Gross Margin	73.6%	70.2%		71.4%	72.6%	
EBITDA	227	270	-15.9%	913	847	7.8%
EBITDA Margin	23.1%	22.8%		20.0%	20.7%	
Net Profit	-218	199	-209.4%	531	381	39.3%
Net margin	-22.2%	16.8%		11.6%	9.3%	
<b>Net Profit (Adjusted)</b>	<b>151 #</b>	<b>199</b>	<b>-24.3%</b>	<b>568 #</b>	<b>555 #</b>	<b>2.4%</b>
Net margin (Adjusted)	15.3%	16.8%		12.5%	13.5%	
R&D	55	61	-8.7%	278	284	-1.9%
R&D as % of Net Sales	5.6%	5.1%		6.1%	6.9%	
EPS (Diluted) IN \$	(0.1)	0.1	-209.4%	0.2	0.2	39.3%
EPS (Diluted) IN \$ (Adjusted)	0.1 #	0.1	-24.3%	0.2 #	0.2 #	2.4%

#

For Full year FY19, adjusted net profit excludes USD 148 Mn provision related to Modafinil settlement in US.

For :Full year FY20 adjusted net profit excludes USD 37 Mn provision (related to Dusa US DoJ settlement of USD 23 Mn and Indirect Tax provision of USD 14 Mn in India)

For Q1 FY21 adjusted net profit excludes for USD 478 Mn provision related to Taro US DoJ settlement.

# Sales Breakup Q1 FY21




( All Figures in USD. Mn )

	Q1 FY21	Q1 FY20	CHANGE	FY20	FY19**	CHANGE
<b>Formulation</b>						
India	315	333	-5%	1,369	1,051	30%
US	282	424	-34%	1,487	1,526	-3%
Emerging Markets	173	194	-11%	776	767	1%
ROW	136	167	-19%	638	494	29%
<i>Sub-total</i>	<b>906</b>	<b>1,117</b>	<b>-19%</b>	<b>4,270</b>	<b>3,837</b>	<b>11%</b>
Bulk	73	66	10%	270	247	9%
Others	6	4	33%	19	17	9%

<b>Gross Sales</b>	<b>984</b>	<b>1,187</b>	<b>-17%</b>	<b>4,559</b>	<b>4,101</b>	<b>11%</b>
--------------------	------------	--------------	-------------	--------------	--------------	------------

\*\*Full year FY19 – Includes a one-time sales reduction of USD 155 mn related to change in distribution for India business



# Includes Western Europe, Canada, Japan, Australia, New Zealand and other markets

# Key Milestones targeted for future

## US Business

- Enhance share of specialty/branded business
- Continue to focus on complex generics and high entry barrier segments
- Ensure broad product offering to customers across multiple dosage forms

## India Business

- Focus on productivity enhancement
- Maintain leadership position in a fiercely competitive market
- Continuously innovate to ensure high brand equity with doctors
- Continue to evaluate in-licensing opportunities for latest generation patented products

## EM & RoW Business

- Gain critical mass in key markets
- Enhance product basket in emerging markets
- Focus on profitable growth

# Key Milestones targeted for future

## Global Consumer Healthcare

- Maintain leadership in existing markets through focus on innovative solutions
- Enhance presence in high growth markets

## R&D

- Focus on developing complex products across multiple dosage forms
- Invest to further build the specialty pipeline

## Regulatory/ Quality

- Ensuring 24x7 compliance to cGMP is imperative for a global business
- Continuously enhance systems, processes, human capabilities to ensure compliance with global regulatory standards

## Financial

- Target sustainable and profitable growth
- Focus on improving ROCE

# Sun Pharma at a glance



4<sup>th</sup> Largest Global Specialty Generic Company\*

US

- Ranked 9<sup>th</sup> in US Generics Market<sup>##</sup>

India

- No. 1 Pharma Company in India

Emerging Markets

- Amongst the largest Indian Pharma Company in Emerging Markets

Rest of World

- Expanding presence in Rest of World

Manufacturing Footprint

- 43 manufacturing sites across the world

Market Presence

- Presence in more than 100 countries across branded and generic markets

Employees

- 36,000+ global employee base

Quality Compliance

- Multiple manufacturing facilities approved by various regulatory authorities across the world including USFDA

R&D and Manufacturing

- Capabilities across dosage forms like injectables, sprays, ointments, creams, liquids, tablets and capsules

Addressable Segments

- Specialty products, branded generics, complex generics, pure generics & APIs

\*Source: Evaluate Pharma Estimates for 12 months ended Dec 2019

## Source: IQVIA data for 12 months ended April 2020



# Thank You!

**For more information please contact:**

**Investors:**

**Nimish Desai**

Tel : +91 22 4324 4324, Ext 2778

Tel Direct +91 22 43242778

[nimish.desai@sunpharma.com](mailto:nimish.desai@sunpharma.com)

**Corporate Address:**

**SUN HOUSE**, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063

© 2016 Sun Pharmaceutical Industries Limited., All Rights Reserved.

"SUN Pharma", The Sun Pharmaceutical Industries Logo are trademarks of Sun Pharmaceutical Industries Limited.

This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners.

NSE:SUNPHARMA, BSE: 524715, Reuters: SUN.BO, Bloomberg: SUNP IN

CIN: L24230GJ1993PLC019050

[www.sunpharma.com](http://www.sunpharma.com)